EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CHD4 Orchestrates Chromatin Remodeling to Activate the c‐Myc Signaling Pathway in Cancer Pathogenesis

Pinggang Ding, Yuhao Cao, Zihao Liu, Jingru Xie, Lingling Liu, Shanliang Sun, Xichao Yu, Zhendong Deng, Zhimin Fan, Ye Yang, Chunyan Gu

MedComm – Oncology · 2026-06 · 5 (2)

DOI: 10.1002/mog2.70073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 14.05.2026. Verfasst von Pinggang Ding und 10 weiteren Autor:innen. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromatin abnormalities are a hallmark of cancer, but the role of the chromatin remodeler CHD4 in multiple myeloma (MM) remains unclear. This study aims to elucidate how CHD4 drives MM progression and to explore targeted therapeutic strategies. Using CHD4 overexpression and knockdown models in MM cell lines, we found that elevated CHD4 correlates with poor prognosis and increased proliferation. Mechanistically, we performed chromatin profiling and luciferase reporter assays to show that the ATPase domain of CHD4 resolves G‐quadruplex structures in the c‐Myc promoter, thereby enhancing chromatin accessibility. Co‐immunoprecipitation (Co‐IP) and chromatin immunoprecipitation (ChIP) further revealed that CHD4 stabilizes c‐Myc activity through liquid‐liquid phase separation (LLPS), increasing c‐Myc chromatin retention and promoter occupancy. To identify CHD4 targets, we integrated RNA‐seq with chromatin profiling. Structure‐based drug design identified luteolin 7‐O‐glucuronide (LUT) as an inhibitor of CHD4's ATPase domain and idarubicin (IDA) as an inhibitor of its chromatin‐interaction domain; combination treatment synergistically suppressed MM proliferation in adoptive B‐cell transfer, xenograft, and 5TMM3VT mouse models. Our findings establish CHD4 as a key oncogenic driver in MM and propose a LUT/IDA combination as a precision medicine strategy, advancing the understanding of chromatin remodeling in cancer.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ding, P., Cao, Y., Liu, Z., Xie, J., Liu, L., Sun, S., Yu, X., Deng, Z., Fan, Z., Yang, Y., & Gu, C. (2026). CHD4 Orchestrates Chromatin Remodeling to Activate the c‐Myc Signaling Pathway in Cancer Pathogenesis. MedComm – Oncology, 5(2). https://doi.org/10.1002/mog2.70073

Vancouver

Ding P, Cao Y, Liu Z, Xie J, Liu L, Sun S, et al. CHD4 Orchestrates Chromatin Remodeling to Activate the c‐Myc Signaling Pathway in Cancer Pathogenesis. MedComm – Oncology. 2026;5(2). doi:10.1002/mog2.70073

BibTeX
@article{Ding2026,
  author = {Ding, Pinggang and Cao, Yuhao and Liu, Zihao and Xie, Jingru and Liu, Lingling and Sun, Shanliang and Yu, Xichao and Deng, Zhendong and Fan, Zhimin and Yang, Ye and Gu, Chunyan},
  title = {CHD4 Orchestrates Chromatin Remodeling to Activate the c‐Myc Signaling Pathway in Cancer Pathogenesis},
  journal = {MedComm – Oncology},
  year = {2026},
  volume = {5},
  number = {2},
  doi = {10.1002/mog2.70073}
}
Kostenlos starten →